Low Dose Bromocriptine (Parlodel™)

February 25, 2010 by admin  
Filed under Immunotheraphy

Low Dose Bromocriptine (Parlodel™)
Reprogramming hormone assembly lines

Based on research literature and clinical experience, bromocriptine may be used to restore strength and stamina in many cancer patients. Bromocriptine may benefit cancer patients in more than one way.

Prolactin is spontaneously overly secreted in some lung cancer patients. This excess secretion causes breast tenderness and enlargement. Premarin may cause breast tenderness and breast enlargement in men, but this effect is mediated by way of prolactin. If prolactin is blocked with bromocriptine, estrogen may be employed for its immune enhancing effects without fear of feminizing or prolactogenic effects in either sex.

A cell population, the somatomammatrophs, in the master gland, the hypophysis, has a pleuripotential capability to secrete either prolactin, or somatotropin, or both. The relative ratio of the production and secretion of these two hormones appears to have frequent marked clinical consequences.

In old age and cancer, somatomammatrophs secrete mostly prolactin. Prolactin is the hormone secreted in pregnancy. It helps establish a state where the mother’s immune system tolerates the progressive growth of the baby. Somatotropin is the trophic (nourishing) hormone of the thymus gland, the master gland of immunity.

Loss of somatotropin secretion leads to loss of physical strength and stamina. There is an actual decrease in muscle mass. Patients get flabby and indolent. Their sense of well being may be very seriously compromised by weakness and loss of stamina.

Based on extensive observation of strength and energy restoration in cancer and autoimmune patients, bromocriptine is capable of restoring the youthful ratio of bromocriptine / prolactin secretion, providing in cancer patients a return of the lost vigor of months or even years earlier. Not surprising from the known effects of bromocriptine as a stimulant of growth hormone secretion, objective evidence of improved surface labeling (maturation) of lymphocytes is frequently observed in cancer patients to whom bromocriptine is prescribed.

CD2, CD3, CD4 (helper cells) and CD56 (natural killer cells) frequently increase.

A pharmacological effect of bromocriptine seems to be a reprogramming of hormone assembly lines inside the somatomammotroph. These hormone assembly lines, which are capable of assembling either prolactin or somatotropin, require a conversion time from prolactin to somatotropin of one to eight weeks, typically 1 1/2 weeks (10 days) to a month (30 days). In many very weak cancer patients, the Center encourages a clinical trial of bromocriptine lasting two months, as a typical experience of no benefit at 10 days frequently converts to significant benefit by 8 weeks.

Bromocriptine is begun slowly. The worst common side effects of bromocriptine are light headedness with standing (orthostatic hypotension) and nausea. Either of these symptoms, if present, usually resolves spontaneously within three or four days.

Comments are closed.